• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Pasithea Therapeutics Corp.

    10/20/22 11:11:32 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KTTA alert in real time by email
    SC 13G 1 n3315_x1-sc13g.htm SC 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    (Amendment No. )*

     

     

     

    Pasithea Therapeutics Corp.
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

    70261F 10 3
    (CUSIP Number)

     

     October 11, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-l(b)

     

    xRule 13d-l(c)

     

    ¨Rule 13d-l(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

       

     

     

     

    CUSIP No. 70261F 10 3  
       

     

    1.    Names of Reporting Persons

     

    Uday Khire

     
     
    2.    Check the Appropriate Box if a Member of a Group (See Instructions)
       
    ¨   (a)  
    x  (b)  
       
       
    3.    SEC Use Only  
       
     
    4.    Citizenship or Place of Organization     United States
           

     

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With:

    5.    Sole Voting Power     1,472,662
       
      6.    Shared Voting Power     0
       
      7.    Sole Dispositive Power   1,472,662
       
      8.    Shared Dispositive Power     0

     

       
    9.    Aggregate Amount Beneficially Owned by Each Reporting Person  1,472,662  
     
    10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).         ¨
     
    11.  Percent of Class Represented by Amount in Row (9)         5.0%
     
     
    12.  Type of Reporting Person (See Instructions)        IN
     
         

     

     
     
     

     

     

    Page 2 of 6 Pages

     

     

       

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Pasithea Therapeutics Corp.

     

    (b)Address of Issuer's Principal Executive Offices

     

    1111 Lincoln Road
    Suite 500
    Miami Beach, Florida 33139

     

    Item 2.

     

    (a)Name of Person Filing (the “Reporting Person”)

    Uday Khire

    (b)Address of Principal Business Office or, if none, Residence

    4 Research Drive, Woodbridge, Connecticut 06525

    (c)Citizenship

    United States

    (d)Title of Class of Securities

    Common Stock, par value $0.0001 per share

    (e)CUSIP Number

    70261F 10 3

    Item 3. If this statement is filed pursuant to §§240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨          Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)¨          Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)¨          Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)¨          Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)¨          An investment adviser in accordance with §240.13d-l(b)(l)(ii)(E);
    (f)¨          An employee benefit plan or endowment fund in accordance with §240.13d-l(b)(l)(ii)(F);
    (g)¨          A parent holding company or control person in accordance with § 240.13d-l(b)(l)(ii)(G);
    (h)¨          A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)¨          A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)¨          A non-U.S. institution in accordance with §240.13d-l(b)(l)(ii)(J).
    (k)¨          Group, in accordance with §240.13d-l(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-l(b)(l)(ii)(J), please specify the type of institution: ______________.

     

     

    Page 3 of 6 Pages

     

       

     

     

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 (the “Issuer”).

     

    (a)Amount beneficially owned:  1,472,662 shares of Common Stock, par value $0.0001 per share

     

    The Reporting Person holds the above-referenced shares in his capacity as representative of the shareholders of AlloMek Therapeutics, LLC (“AlloMek”). The Reporting Person disclaims beneficial ownership of 501,623 of the above-referenced shares, in which he has no pecuniary interest.

     

    On October 11, 2022, the Issuer entered into a Membership Interest Purchase Agreement, dated October 11, 2022 (the “Agreement”), by and among the Issuer, AlloMek, the Persons listed on Schedule 1.1 thereto (each individually a “Seller” and collectively, “Sellers”), and Uday Khire, not individually but in his capacity as the representative of Sellers (the “Representative”), pursuant to which the Sellers sold all of the issued and outstanding equity of AlloMek to the Issuer. Closing of the transactions contemplated in the Agreement occurred on October 11, 2022.

     

    In addition to the above-referenced shares, the Reporting Person also holds warrants to purchase an aggregate of 413,230 shares of Common Stock (“Warrants”) at an exercise price of $1.88 per share, which may be exercised on a cashless basis, for a period of five years commencing on the date of issuance. The Warrants contain a customary 4.99% beneficial ownership blocker provision and are therefore not reflected as beneficially owned by the Reporting Person for purposes hereof.

     

    (b)Percent of class: 5.0%

     

    The information with respect to percentage ownership is based on a total of 29,398,688 outstanding shares of Common Stock, par value $0.0001 per share of Pasithea Therapeutics Corp., representing the sum of (i) 26,698,688 shares of Common Stock, par value $0.0001 per share of Pasithea Therapeutics Corp. outstanding as of August 8, 2022, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 15, 2022, plus (ii) 2,700,000 shares issued on October 11, 2022 in connection with the acquisition of AlloMek as described in the Issuer’s Form 8-K filed with the Securities and Exchange Commission on October 12, 2022.

     

     (c)

     

    The information required by Item 4(c) is set forth in Rows 5-11 of the cover page hereto for the Reporting Person and is incorporated herein by reference for such Reporting Person.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

     

    Page 4 of 6 Pages

     

       

     

     

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

     

    Item 10. Certifications

     

     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

    Page 5 of 6 Pages

     

       

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

     

     

    Dated: October 20, 2022

    Uday Khire

     

     

     

        /s/ Uday Khire              

     

     

       

     

    Page 6 of 6 Pages

     

       

    Get the next $KTTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KTTA

    DatePrice TargetRatingAnalyst
    12/14/2021$3.25Buy
    EF Hutton
    More analyst ratings

    $KTTA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pasithea Therapeutics Corp.

      10-Q - Pasithea Therapeutics Corp. (0001841330) (Filer)

      5/15/25 4:31:35 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.

      SCHEDULE 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

      5/15/25 3:36:45 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.

      SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

      5/12/25 4:08:40 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on Pasithea Therapeutics with a new price target

      EF Hutton initiated coverage of Pasithea Therapeutics with a rating of Buy and set a new price target of $3.25

      12/14/21 8:32:07 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

      -- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases – -- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway – -- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation in IBD -- MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a

      5/20/25 7:01:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

      -- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas ---- Starting dose of 4mg tablet QD (once daily) ---- First trial site in Australia. Four additional sites planned for Australia, South Korea, and U.S. –-- Australian R&D Tax Incentive refund of up to 48.5% of eligible study-related costs expected -- MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today ann

      5/14/25 7:02:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Announces Closing of $5 Million Public Offering

      MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. ("Pasithea," or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the closing of its previously announced public offering of 3,571,428 shares of its common stock (or pre-funded warrants in lieu thereof) and accompanying Series C warrants to purchase up to 3,571,428 shares of common stock and Series D warrants to purchase up to 3,571,428 shares of common stock, at a combined offering price of $1.40 per share of common stock (or per pre-

      5/7/25 5:00:00 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marques Tiago sold $792 worth of shares (960 units at $0.82), decreasing direct ownership by 2% to 40,001 units (SEC Form 4)

      4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

      5/14/25 9:55:17 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Novak Alfred J was granted 3,500 shares (SEC Form 4)

      4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

      6/14/24 5:25:21 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Marques Tiago (Amendment)

      4/A - Pasithea Therapeutics Corp. (0001841330) (Issuer)

      4/5/24 9:45:31 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pasithea Therapeutics Corp.

      SC 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

      11/14/24 3:32:41 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pasithea Therapeutics Corp. (Amendment)

      SC 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

      1/13/23 8:02:14 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Pasithea Therapeutics Corp. (Amendment)

      SC 13D/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

      1/10/23 3:55:25 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Financials

    Live finance-specific insights

    See more
    • Pasithea Therapeutics Acquires AlloMek Therapeutics

      -- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) -- Management to Host an Investor Webcast Today at 9 a.m. ET MIAMI BEACH, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it acquired AlloMek Therapeutics, LLC ("AlloMek"), a privately-he

      10/12/22 8:00:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

      - Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth -- Closing consideration of 3.26 million shares of Pasithea common stock -- Pasithea to hold a webcast on June 22 at 9 a.m. ET to discuss the transaction - MIAMI BEACH, Fla., June 22, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), today announced its acquisition of Alpha-5 integrin, LLC ("Alpha-5"), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of am

      6/22/22 8:00:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

      MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other indications, announced today that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company's Scientific Advisory Board. Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology (Division of Neuro-Oncology), Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights

      9/3/24 8:02:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Announces Results from 2023 Annual Meeting

      SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA), today announced that it held its annual meeting of stockholders (the "Annual Meeting") on December 19, 2023. Over 70% of the Company's shares of common stock were represented at the Annual Meeting. More than 95% of shares voted were cast "for" the election of directors (Proposal 1), and over 85% "for" Proposals 2, 3 and 6 (collectively, the "Approved Proposals"). The Approved Proposals related to the following matters: appointment of the Company's proposed slate of directors;-  Dr. Tiago Reis Marques;-  Prof. Larry Steinman;-  Simon Dume

      12/19/23 5:19:00 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors

      MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system ("CNS") disorders, today announced that Alfred J. Novak was appointed to its Board of Directors (the "Board"). Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022. Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies. Mr. Novak brings financial acumen and ext

      9/20/22 8:00:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care